AI in Drug Discovery Market Worth US$ 4,056.2 Million by 2031: Visiongain Research Inc.

Visiongain has published a new report on Global AI in Drug Discovery Market Report Forecast 2021-2031. Forecasts by Technology ($ Mn), by Application ($ Mn), by Therapeutic Areas ($ Mn), and by End User ($ Mn). Plus, profiles of Leading AI in Drug Discovery Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Visiongain’s lead pharma analyst says: ‘The Global AI in Drug Discovery market was valued at US$ 230.4million in 2021 and is projected to reach at a market value of US$4,056.2 million by 2031.

Download Exclusive Sample of Report @

Drug discovery is the first step in the process of identifying a new candidate therapeutic for the treatment of diseases. Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth. Additionally, rising need for decreasing the cost of novel drug discovery and production, analysis of immense data generated by the molecule screening processes and preclinical studies are the other factors that support the growth of the market. However, lack of skilled labor operating AI and huge investments are some of the factors that might restrict the growth of the market to some extent during the forecast period’.

COVID-19 Impact on Global AI in Drug Discovery Market

The impact of COVID-19 pandemic is there on almost all the sectors and assessing its impact on the market would be uncertain as there is no knowledge about how long this pandemic stay would. Visiongain believes that considering all the factors there can be four scenarios in which the global market can react to the current crisis and that can be ‘V’ shaped recovery, ‘U’ shaped recovery, ‘L’ shaped recovery and ‘W’ shaped recovery. The functioning of the AI in Drug Discovery was regular during the pandemic situation as there was rising demand for novel drugs for the treatment of critical diseases. In addition, the clinical progress of various drugs also continued with the use of AI but with new obstacles caused due to the pandemic and its effects. Many global companies reported challenges in clinical trial execution, including patient recruitment, enrolment, data collection and/or follow-up. In addition, managing and reacting to the ongoing public health crisis caused by COVID-19 has become the priority for many policymakers, regulators, and public sector payer’s. Thus, this could result in a delay for drug candidates outside of the COVID-19 space.

How the Global AI in Drug Discovery Market report helps you

In summary, our 1220+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for Technology, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for Therapeutic Area, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for Global AI in Drug Discovery Market, with forecasts for End User, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the AI in Drug Discovery market in North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 18 of the major companies involved in the Global AI in Drug Discovery Market.

Get Detailed TOC @

Market Drivers

Development of a new drug is difficult and time-consuming task. With the use of AI some of the tasks can be eased such as drug development, designing, drug repurposing and selection of the population for clinical trials. AI tools are used to sort and cross-reference data and deliver the targeted results, that can escalate the process of drug discovery. In addition, AI tools also helps to integrate and streamline the data across disparate processes. AI also helps to reduce the errors and bias caused by humans in classical methods of drug development. Deep learning platform has given suitable results in finding therapeutic and toxicological effects of a drug molecule. Thus, rising focus of pharmaceutical companies to reduce the cost of drug discovery & development supports the uptake of AI in the drug development process.

Utilization of AI in Drug discovery helps the pharmaceutical companies to ensure that their projects are completed on time and on schedule with quality. Drug discovery is a complicated endeavor requiring different teams working efficiently with each other. If one team is behind schedule, this has a knock-on effect, ultimately slowing down the process further down. More importantly, the productivity of the entire organization is affected. Thus, another key driver for the incorporation of AI in drug discovery market is the efficient turnaround times of the results for the commercialization of the final product.

Market Opportunities

Increased understanding of disease biology through genomic analysis has identified many subsets of patients within a disease. Companies are now targeting these subsets of patients with new treatments, aiming at smaller patient population but with higher priced drugs. A similar trend is the development of drugs for orphan disease or rare disease where often high unmet treatment needs exist. Trends such as these offers both opportunities and challenges. It has been reported that there are about three times as many drugs for rare diseases in the pipeline as compared to the last decade. Out of more than 8,500 new drugs in development, 1,800 will tackle rare diseases. Moreover, many of the drugs in the pipeline are innovative, first-in-class drugs as opposed to “me-too” drugs. Thus, rising focus of the companies on innovative drugs will generate new opportunities for the uptake of AI in the drug discovery process in coming years.

Need industry data? Please contact us today.

Competitive Landscape

The global AI in drug discovery market is a fragmented market with the presence of many global and local players engaged in developing platforms to come up with new and innovative products for the treatment of rare diseases. Some of the key players operating in this market are Deep Genomics, Microsoft Corporation, Exscientia, Atomwise, Inc., Deep Genomics, IBM Corporation, GNS Healthcare, Benevolent AI, and others. The companies are investing heavily to expand their technological infrastructure for the drug discovery and increase the adoption of technology to meet the continuous growing demand of drugs for the treatment of various diseases.  

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Find more research reports on the Artificial Intelligence Industryplease click on the following links: 

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: [email protected]

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.


Sara Peerun

Commercial Director

Visiongain Inc.

Tel: + 44 207 549 9987

USA Tel: + 1 718 682 4567

EU Tel: + 353 1 695 0006

Email: [email protected]


Follow Us: LinkedIn | Twitter

SOURCE Visiongain Limited.